مباشر
FierceBiotechNovartis narrows focus for anticoagulant after failure to best Eliquis in phase 3 trialAgilentAgilent Technologies, Inc. $A Shares Sold by OVERSEA CHINESE BANKING Corp Ltd - MarketBeatWatersWaters introduces biphenyl LC columns with low UV bleed and wide pH stability for improved aromatic separations - Chromatography TodayLonza NewsSimulations Plus partners with Lonza and FDA on drug formulation research - Investing.com IndiaLonza NewsAcetylacetone Market: Asia Dominates with Lonza, Daicel, Wacker Boosting Specialty Chemicals Demand - openPR.comIlluminaCSR News Feed | Explore the latest corporate social responsibility news from Illumina - IlluminaThermo FisherThermo Fisher (TMO) Reports Q1: Everything You Need To Know Ahead Of Earnings - StockStory10x Genomics Blog10x Genomics: Atera Platform Launch Advances Spatial Biology With Single-Cell Resolution At Scale - Pulse 2.0Lonza NewsSimulations Plus partners with Lonza and FDA on drug formulation research - Investing.com AustraliaIlluminaCSR News Feed | Explore the latest corporate social responsibility news from Illumina - IlluminaFierceBiotechAACR: Revolution sees pancreatic cancer win as 'tip of the iceberg' as RAS wave risesFierceBiotechRacing toward first FDA nod for autoimmune CAR-T, Kyverna bolsters lead with full SPS dataset
Agilent ٥ يناير ٢٠٢٦

Citi Maintains Agilent Technologies(A.US) With Buy Rating - 富途牛牛

Citi Maintains Agilent Technologies(A.US) With Buy Rating - 富途牛牛

المصدر
المحتوى غير متاح. يرجى الرجوع إلى المصدر الأصلي.